[Treatment in relapsed multiple myeloma; bortezomib, lenalidomide, thalidomide]
Andersson PO, Blimark C, Veskovski L, Strandell A, Samuelsson O, Svanberg T, Liljegren A
Record ID 32011001145
English
Authors' recommendations:
The treatment of patients with relapsed multiple myeloma with bortezomib, lenalidomid or talidomide can prolong overall survival (6-9 months) and the time to progression to some extent, and result in a better tumour cell response in comparison to conventional corticosteroid therapy. The level of evidence is low with regard to survival and moderate with regard to tumour cell response.
Adverse effects are common and can be serious.The cost of treatment is high.
Details
Project Status:
Completed
URL for project:
http://www.sahlgrenska.se/upload/SU/HTA-centrum/HTA-rapporter/HTA-rapport%20%20Myelom%202011-02-21%20till%20publicering.pdf
Year Published:
2011
URL for published report:
http://www.sahlgrenska.se/sv/SU/Forskning/HTA-centrum/Statements-on-HTA-reports-/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
MeSH Terms
- Antineoplastic Agents
- Multiple Myeloma
- Pyrazines
- Recurrence
- Thalidomide
- Lenalidomide
- Bortezomib
- Angiogenesis Inhibitors
Contact
Organisation Name:
The Regional Health Technology Assessment Centre
Contact Address:
The Regional Health Technology Assessment Centre, Region Vastra Gotaland, HTA-centrum, Roda Straket 8, Sahlgrenska Universitetssjukhuset, 413 45 GOTHENBORG, Sweden
Contact Name:
hta-centrum@vgregion.se
Contact Email:
hta-centrum@vgregion.se
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.